...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith AGM Dec 15
Reply New Message
Back To Forum List View
Icon president Zenith AGM Dec 15
1
BearDownAZ
Oct 06, 2016 11:41PM
Icon president Re: Zenith AGM Dec 15
1
SanFrancisco99
Oct 15, 2016 11:12PM
Re: Zenith AGM Dec 15
4
Nextblockbuster
Oct 16, 2016 04:22PM
Icon president Re: Zenith AGM Dec 15
2
SanFrancisco99
Oct 17, 2016 10:24AM
Re: Zenith AGM Dec 15
4
masila
Oct 17, 2016 08:00PM
Icon president Re: Zenith AGM Dec 15
3
BearDownAZ
Oct 18, 2016 09:25AM
Icon president Re: Zenith AGM Dec 15
4
SanFrancisco99
Oct 19, 2016 10:47AM
Icon president Re: Zenith AGM Dec 15
2
SanFrancisco99
Oct 19, 2016 11:06AM

Well, they have at least one event planned that they haven't "confirmed" yet. Poster presentation on November 30th.

EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

November 29 – December 2, 2016; Munich, Germany

The investigational drug ZEN-3694, a novel BET-bromodomain inhibitor, inhibits multiple tumor immune escape mechanisms and has the potential to combine with immunotherapies

S. Attwell, K. Norek, R. Jahagirdar, C. Calosing, S. Lakhotia, E. Campeau, H. Hansen

4 Recommendations
Re: Zenith AGM Dec 15
6
general360
Oct 19, 2016 05:07PM
Icon president Re: Zenith AGM Dec 15
4
SanFrancisco99
Oct 20, 2016 12:48AM
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply